Sköld, Camilla
Corvigno, Sara
Dahlstrand, Hanna
Enblad, Gunilla
Mezheyeuski, Artur
Sundström-Poromaa, Inger
Stålberg, Karin
Tolf, Anna
Glimelius, Ingrid
Koliadi, Anthoula
Funding for this research was provided by:
Cancerfonden (CAN 2017/383, CAN 2017/383)
Lions foundation Uppsala
Uppsala University
Article History
Received: 1 December 2023
Accepted: 24 March 2024
First Online: 5 April 2024
Declarations
:
: HD had served on advisory boards for Astra Zeneca and has held educational events supported by Roche and GSK; all unrelated to the current study. IG has research support from Janssen Cilag and Takeda Pharmaceuticals, and support in Pharmacovigilance questions from Lokon Pharma; all unrelated to the current study. ISP has served on advisory boards or acted as invited speaker at scientific meetings for Asarina Pharma, Bayer Health Care, Gedeon Richter, Novartis, Peptonics, Shire/Takeda, and Sandoz; all unrelated to the current study. All other authors declare they have no conflicts of interest.
: Ethical approval was obtained from the ethics committees of Karolinska Institutet (ethical permit number 2012/539-31/1 and complementary approval 2018/2061-32) and of Uppsala University (ethical permit number 2017/003 and complimentary approval 2019-05942). The need for informed consent from patients was waived by the ethics committees. Authors had access to information that could identify individual participants during data collection (clinical data were obtained from medical records); after data collection was completed, all data was fully anonymized and coded.